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Many pathogens, including the malaria parasite Plasmodium falciparum, display
high levels of polymorphism within T-cell epitope regions of proteins associated with 
protective immunity. The T-cell epitope variants are often non-cross-reactive. Herein, 
we show in a murine model, which modifies a protective CD8 T-cell epitope from the 
circumsporozoite protein (CS) of Plasmodium berghei (SYIPSAEKI), that simultaneous 
or sequential co-stimulation with two of its putative similarly non-cross-reactive altered 
peptide ligand (APL) epitopes (SYIPSAEDI or SYIPSAEAI) has radically different effects 
on immunity. Hence, co-immunization or sequential stimulation in  vivo of SYIPSAEKI 
with its APL antagonist SYIPSAEDI decreases immunity to both epitopes. By contrast, 
co-immunization with SYIPSAEAI has no apparent initial effect, but it renders the immune 
response to SYIPSAEKI resistant to being turned off by subsequent immunization with 
SYIPSAEDI. These results suggest a novel strategy for vaccines that target polymorphic 
epitopes potentially capable of mutual immune interference in the field, by initiating an 
immune response by co-immunization with the desired index epitope, together with a 
carefully selected “potentiator” APL peptide.
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inTrODUcTiOn
Foreign epitopes complexed with host MHC molecules are the target of recognition by cognate 
antigen-specific T cells. The development of effective preventive vaccines requires the induction of 
long-lasting immunity in the human population, with the capacity to induce responses to naturally 
occurring strains of a pathogen bearing different variants of protective epitopes. Pathogens bear-
ing variant epitopes can evade or skew the immune system in a variety of ways leading to loss of 
protective immunity. A direct form of immune evasion involves the mutation of amino acid residues 
that are required for peptide binding to MHC. Other more sophisticated forms of polymorphic 
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immune evasion also exist [reviewed in Ref. (1)]. Altered peptide 
ligand (APL) antagonism involves the concurrent presentation 
of selected closely related epitope variants. This can inhibit T cell 
effector functions such as cytokine production, cytotoxicity, or 
proliferation. The use of APL ligands for immune evasion has 
been well documented across human immunodeficiency virus 
(HIV), hepatitis B and C (HBV and HBC), and malaria parasite 
infections [reviewed in Ref. (1)]. Another form of immune 
evasion, known as “immune interference,” also involves the con-
current or sequential presentation of related epitope variants to 
T cells. Immune interference results a failure to induce memory 
T cells from naive precursors. CD8 T-cell epitope variants causing 
APL antagonism and immune interference have been identified 
in Plasmodium falciparum and are major contributors to the para-
site population structure observed in malaria-endemic regions of 
the world (2, 3).
Variant-specific immunity has been documented for the lead 
preerythrocytic malaria vaccine, RTS,S, which contains a single 
polymorphic variant of the circumsporozoite protein (CS) of P. 
falciparum (4). However, vaccines that target individual vari-
ants provide limited or short-lasting benefit in protection from 
malaria. This occurs because the non-targeted parasite variants 
take over the vacated niches in the vaccine-treated host popula-
tion [discussed in Ref. (1)]. Attempts to provide more broadly 
cross-reactive responses against malaria have included mixing 
polymorphic variants of a single antigenic protein into one 
vaccine formulation, for example, including both the 3D7 and 
FC27 variants of merozoite surface protein 2 from P. falciparum 
into a single recombinant erythrocytic-stage vaccine (5); or mix-
ing multiple target proteins into one formulation, for example, 
including the two key preerythrocytic-stage antigens CS and 
thrombospondin-related adhesive protein (TRAP) (6). Both 
attempts yielded disappointing results, with the combination of 
antigens showing little increase, and in the case of CS and TRAP, 
even a decrease, in immunity. As an alternative, recent studies 
have evaluated whether changing the adjuvant used to deliver a 
protective preerythrocytic Plasmodium berghei CD8 T-cell epitope 
(SYIPSAEKI) in murine models could broaden the pattern of T 
cell cross-reactivity (7). SYIPSAEKI (KI) is the immunodomi-
nant CD8 T-cell epitope of the P. berghei circumsporozoite (CS) 
protein, and the presence of vaccine-induced IFNγ-producing 
splenic T cells to this epitope correlates with protective efficacy 
(8). The contact T cell receptor (TCR) amino acid residue has 
been identified to be position 8, and in recent studies engineered 
amino acid changes to this position resulted in the generation of 
useful variants to model how an amino acid change can lead to 
loss of T cell cross-reactivity, without a decrease in MHC-binding 
capacity (8). Disappointingly, although both pro-inflammatory 
(montanide and poly I:C) and non-inflammatory nanoparticle-
based vaccines induced comparable and robust peptide-specific 
responses to KI, they induced limited cross-reactivity to variants 
SYISAEDI (DI) or SYIPSAEAI (AI) (8). The limited cross-
reactivity was also shown not to be due to holes in the naïve T cell 
repertoire, since vaccines formulated with each APL individu-
ally (including KI, AI, or DI) were capable of inducing robust 
immune responses to the immunizing index APL (7). While 
neither DI nor AI are natural variants, inclusion of such APLs in 
malaria vaccines has the potential to induce a broader spectrum 
of cross-reactive responses different from immunization with 
the index epitope alone. Conversely, if any of the pooled variants 
had antagonistic APL properties, such an approach could restrict 
the spectrum of responses, or turn off preexisting immunity, 
thus inducing immune interference, as has been described for 
naturally occurring variants of CS T-cell epitopes (9). Testing the 
consequences of immunizing with combinations or mixtures of 
APL variants has not been explored in such previous studies.
Understanding the mechanism by which immune interference 
promotes parasite survival and influences parasite population 
dynamics is central to successful vaccine development. In the 
present study, a murine model was utilized to dissect the complex 
patterns of immunity induced by well characterized selected APL 
variants of the P. berghei CD8 T-cell epitope KI, DI, and AI. The 
findings demonstrate a novel vaccination strategy that broadens 
T cell immunity and is resistant to being “turned off ” by immune 
interference. This new vaccination strategy is likely to be of utility 
in tackling diverse pathogens beyond malaria that utilizes APLs 
for immune evasion, such as HIV and hepatitis C [reviewed in 
Ref. (1)].
aniMals anD MeThODs
animals
Female BALB/c (H-2d) mice, 6–10  weeks of age were sourced 
from the Walter and Eliza Hall Institute, Melbourne, VIC, 
Australia, or bred at the Austin Research Institute Biomedical 
Animal Research Laboratory. The study was approved by Austin 
Research Institute Animal Care and Use Committee approved all 
animal procedures.
Peptides
The immunodominant CD8 epitope of P. berghei circumsporozo-
ite protein SYIPSAEKI, its variants SYIPSAEDI and SYIPSAEAI, 
and the influenza CD8 epitope NPKd (TYQRTRALV) were 
synthesized by to >99% purity by Auspep (Melbourne, VIC, 
Australia). Peptides were confirmed to be non-toxic at the doses 
used by incubation of splenocytes overnight and assessment of 
impairment of ConA responses by ELISPOT.
immunizations
Bone marrow-derived dendritic cells (DCs) were generated as 
previously described 10) by culturing bone marrow cells from 
female BALB/c mice for 6–8 days in RPMI 1640 (Gibco, USA) 
supplemented with 10% heat inactivated fetal calf serum (CSL, 
Australia), 20 mM HEPES buffer (JRH, USA), 4 mM l-glutamine, 
100 U/mL penicillin, 100 mg/mL streptomycin sulfate, 100 mM 
β-mercaptoethanol (all Sigma, Australia), 1,000  U/mL granu-
locyte and macrophage colony stimulating factor (GM-CSF, 
Pharmingen, USA), and 10  ng/mL of interleukin-4 (IL-4, 
Pharmingen, USA). Female mice were used to avoid rejection 
of the transferred DCs. DCs were CD11c+MHCII+ and Gr1− 
with the majority (>80%) co-expressing CD11b+ indicating 
an inflammatory DC phenotype (data not shown). Harvested 
DCs were pulsed with 5  µg/mL peptide at 37°C for 1  h. For 
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co-presentation DCs were pulsed with one peptide for 1 h, fol-
lowed by the variant peptide for a further 2  h. No phenotypic 
changes were observed (using markers CD11c, CD11b, Gr1, 
MHCII, CD40, CD80, or CD86) following the peptide pulse for 
any of the peptides used, and no changes in inflammatory (IL6, 
TNF, and IL1) or suppressor cytokines (IL-10) in the supernatant, 
or changes in DC viability (by trypan blue). 106 DCs in 100 µL 
sterile PBS were injected intradermally into the hind footpads 
(50  µL per footpad) or into the base of the tail. Experiments 
involving immunization with one peptide or peptide combina-
tion on day 0 followed by booster immunization with another 
peptide on day 14 included control groups that received the same 
peptide or peptide combination as single immunization on day 0 
only and another group that received a single immunization with 
the booster peptide on day 14 only. For all sequential immuniza-
tions, ELISPOT assays were performed between days 14 and 17 
following the last immunization.
Ex Vivo elispot assays
ELISPOT assays were carried out in 96 well mixed acetate 
plates (Millipore, Watford, UK) as previously described (8). 
MAIPS4510 plates, pretreated with 50  μL/well methanol, 
were used for IFNγ assays; IL-4 and IL-10 secretion was 
assessed in MAHAS4510 plates. Plates were coated with 5 µg/
mL anti-mouse IFNγ mAb (Mab AN18, Mabtech), 10 µg/mL 
anti-mouse IL-4 mAb (clone BVD4-1D11, Pharmingen), or 
10 µg/mL anti-mouse IL-10 mAb (Pharmingen) and blocked 
with culture media RPMI 1640 (Gibco, USA) supplemented 
with 1% heat inactivated mouse serum, 20 mM HEPES buffer 
(JRH, USA), 4 mM l-glutamine, 100 U/mL penicillin, 100 mg/
mL streptomycin sulfate, and 100 mM β-mercaptoethanol (all 
Sigma, Australia). Around 500,000 freshly isolated splenocytes 
were cultured in the presence of 10−5–10−11 M peptide in tripli-
cate or quadruplicate wells. Plates were incubated at 37°C, 5% 
CO2 for 16 h for IFNγ assays, 24 h for IL-4, and 48 h for IL-10 
assays. In preliminary assays, cognate responses from splenic 
T cells from animals immunized with KI, AI, or DI alone were 
eliminated when splenocytes were depleted of CD8 T cells 
(Dynabeads, UK) prior to the assay, confirming responses to 
these minimal CD8 T cell peptide epitopes come from CD8 T 
cell as expected.
For In Vitro antagonism assays
Splenocytes were restimulated with a suboptimal concentration 
of the index peptide KI for 1 h; the altered variant DI was added at 
different concentrations and incubated for a further 16 h washed, 
counted, and plated out as per (9).
Plates were incubated with 1 µg/mL biotinylated anti-mouse 
IFNγ mAb (Mab R4-6A2-Biotin, Mabtech, Sweden), biotinylated 
anti-mouse IL-4 mAb (clone BVD6-24G2-biotin, Pharmingen, 
USA), or biotinylated anti-mouse IL-10 mAb (Pharmingen, 
USA), followed by 1  µg/mL streptavidin–alkaline phosphatase 
(AP) (Mabtech, Sweden) for IFNγ assay or 0.1 µg/mL extravidin–
AP (Sigma, USA) for IL-4 and IL-10 assays and developed using 
a colorimetric AP Kit (BioRad, Hercules, CA, USA). The number 
of spot forming units (SFU) per well was scored using the AID 
ELISPOT reader (Autoimmun Diagnostika GmbH, Germany) 
with AID ELISpot software version 2.9 (Autoimmun Diagnostika 
GmbH, Germany).
statistical analysis
All statistical analyses were carried out using GraphPad Prism 
(version 6.01). ELISPOT data were analyzed using two-way 
ANOVA followed by Tukey’s post hoc test for comparison of all 
groups or Dunnett’s post  hoc test for comparison to the index 
peptide. The significance level used was (α) = 0.05 for all statisti-
cal tests.
resUlTs
co-immunization with Variants Ki and Di 
impairs the generation of Ki-specific 
iFnγ-secreting cD8 T cells
To address the question whether co-immunization with epitope 
variants SYIPSAEKI (KI) and SYIPSAEDI (DI) could broaden 
the immune response, we immunized BALB/c mice with DCs 
loaded with both peptides KI and DI. To minimize competition 
for MHC class I binding clefts, and to ensure KI presentation, 
DCs were pulsed first with variant KI for 1 h, followed by variant 
DI for another 2 h at equimolar concentrations (0.5 × 10−6 M). 
Control mice received DCs pulsed with KI or DI alone or without 
peptide. No KI-specific IFNγ secreting cells were detected in 
mice immunized with DI-pulsed DCs, confirming that priming 
with DI did not induce cross-reactive T cells. DCs pulsed with 
KI alone induced strong KI-specific IFNγ responses, while DCs 
co-presenting both KI and DI (KI/DI) induced significantly less 
KI-specific IFNγ-producing T cells (Figure 1A, p < 0.001). This 
significant reduction in KI-specific IFNγ responses was still evi-
dent 6 weeks after immunization (Figure 1B, n = 3, p < 0.001). 
KI-specific IFNγ responses could not be restored to normal level 
by using more antigen (Figure 1C, n = 3). To rule out peptide 
competition for H-2Kd binding, DCs were also pulsed separately 
with variant KI or DI for 1 h, washed, and then mixed at 1:1 ratio 
(KI + DI) immediately before injection. Control mice received (i) 
DCs pulsed with KI + DI, (ii) DCs pulsed with either variant KI 
or DI alone as positive controls, or (iii) DCs without peptide as a 
negative control. Figure 1D shows that KI-specific IFNγ-secreting 
cells were reduced irrespective of whether DCs had been loaded 
with KI and DI together (p = 0.009) or separately (p < 0.001). 
No KI-specific IFNγ secretion was observed in DI-immunized 
mice as observed previously. These data suggest that DI inter-
fered with priming of KI-specific IFNγ secreting T cells in vivo 
when presented together with KI on the same or different APC. 
Therefore, this interference is unlikely to have been caused by 
peptide competition for MHC binding. Furthermore, no interfer-
ence with KI-specific T cell priming was observed with DCs co-
presenting KI together with the unrelated H-2Kd-restricted CD8 
T-cell epitope NPKd (TYQRTRALV) from the influenza A virus 
nucleoprotein (aa 147–155) (11), a peptide with strong binding 
affinity for H-2kd (12, 13). The immune interference observed 
with KI +  DI immunization appeared therefore unlikely to be 
due to the DC-loading protocol but suggests inhibitory effects 
were mediated specifically by variant DI.
A C
B D
FigUre 1 | impaired iFnγ secretion following co-immunization with peptides Ki and Di presented on the same or on different Dc. BALB/c mice were 
immunized with dendritic cells (DCs) pulsed with either peptide KI or DI alone or with DCs pulsed with KI for 1 h followed by DI for 2 h. Control mice received DCs 
without peptide. IFNγ secretion was assessed by ex vivo ELISpot assay (a) 14 days or (B) 41 days after immunization. (c) IFNγ secretion upon restimulation with 
peptide KI at concentrations ranging from 10−9 to 10−5 M was assessed by ex vivo ELISpot assay 13 days after immunization. (D) BALB/c mice were immunized 
with DCs pulsed with either peptide KI or DI alone, with DCs pulsed with KI for 1 h then with DI for 2 h (KI/DI), or with a 1:1 mixture of DCs pulsed separately with KI 
or DI (KI + DI). IFNγ secretion was assessed by ex vivo ELISpot 17 days after immunization. Mean spot forming units ± SD are shown (n = 3 mice per group). 
Two-way ANOVA with Tukey’s (a,B,D) or Dunnett’s (c) multiple comparison test was used to test for statistical significance when comparing all groups or when 
compared to the group immunized with the index peptide KI, respectively.
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co-immunization with Variants Ki and ai 
Does not interfere with Ki-specific or 
ai-specific T cell Priming
When we tested the effect of co-immunization of KI with another 
variant SYIPSAEAI (AI), we observed a different effect. Using 
the same immunization strategy as above, DCs were pulsed with 
KI for 1  h followed by AI for 2  h at equimolar concentration 
(5 × 106 M) (KI/AI). Control mice were immunized with DCs 
pulsed with KI and AI alone or without peptide. KI-specific 
IFNγ responses were assessed by ex vivo ELISpot assay. We 
observed no significant difference in KI-specific IFNγ responses 
between mice immunized with KI or KI/AI at 2 (Figure 2A) or 
5  weeks (Figure  2B) post-immunization. Titration of peptide 
KI from 5 × 10−9 to 5 × 10−6 M for ex vivo stimulation showed 
a similar reactivity pattern for KI-immunized mice and KI/
AI-immunized mice at all concentrations tested (Figure  2C). 
Together, these data suggest that epitope variant AI does not 
interfere with KI-specific T cell priming when presented together 
with KI in vivo, indicating a functional difference between the 
two altered peptide variants AI and DI. To assess whether KI 
interfered with AI-specific priming, splenocytes from mice 
immunized with KI/AI or AI alone were assessed for AI-specific 
IFNγ responses by ex vivo ELISpot assay. Titration of peptide AI 
showed a similar reactivity pattern for AI- or KI/AI-immunized 
mice at all concentrations tested (Figure 2D). These results show 
that co-presentation of peptides KI and AI does not interfere 
with T cell priming.
Across experiments, mice immunized with KI-pulsed DC var-
ied in their KI-specific IFNγ responses. Figure 3A shows pooled 
data from 12 experiments. The mean KI-specific IFNγ response in 
mice immunized with DC pulsed KI/DI (mean 185 ± 146 SFU/
million) was significantly lower compared to those immunized 
with KI alone (mean 330 ±  164  SFU/million; p <  0.001). By 
contrast, KI-specific IFNγ responses in mice co-immunized with 
KI/AI (mean 285 ± 197 SFU/million) was comparable to those 
immunized with KI alone (Figure 3A).
Variants Ki and Di show Potential Mutual 
inhibitory effects on T cell Priming
We next tested the effect of KI/DI co-presentation of the priming 
on DI-specific IFNγ responses after immunization with DCs co-
presenting KI and variant DI (KI/DI) or DI alone. Mice immunized 
with KI/DI had significantly fewer DI-specific IFNγ secreting 
cells than mice immunized with DI alone (Figure 1A, p < 0.001), 
an effect that was less evident at 6  weeks post-immunization 
(Figure 1B, p = 0.05). Across experiments KI/DI immunization 
elicited significantly lower DI-specific IFNγ responses (mean 
98 ±  83  SFU/million) compared to mice immunized with DC 
pulsed with DI alone (mean 164 ± 107 SFU/million; Figure 3B; 
p <  0.01). Although we cannot exclude that this effect might 
have been due to DC being pulsed with KI first followed by DI, 
this observation suggests that altered peptide variants KI and DI 
could be mutually antagonistic/immune interfering during T cell 
priming in  vivo. KI- or DI-specific IFNγ responses following 
A C
B D
FigUre 2 | co-immunization with Ki and ai does not interfere with T cell priming. BALB/c mice were immunized with dendritic cells (DCs) pulsed with either 
peptide KI or AI alone or with DC pulsed with KI for 1 h then with AI for 2 h. Control mice received DCs without peptide. (a) 12 days or (B) 31 days post-
immunization IFNγ secretion was assessed by ex vivo ELISpot by restimulation with peptide KI at 0.5 µg/mL. (c) BALB/c mice were immunized with DCs pulsed 
with either peptide KI (triangles) or with DC pulsed with KI for 1 h then with AI for 2 h (squares). Control mice received non-pulsed DCs (open circles). IFNγ secretion 
was assessed by ex vivo ELISpot by restimulation with peptide KI at concentrations ranging from 5 × 10−9 to 5 × 10−6 M 10 days post-immunization. (D) BALB/c 
mice were immunized with DCs pulsed with either peptide AI (triangles) or with DC pulsed with KI for 1 h then with AI for 2 h (squares). Control mice received 
non-pulsed DCs (open circles). IFNγ secretion was assessed by ex vivo ELISpot by restimulation with peptide AI at concentrations ranging from 5 × 10−9 to 
5 × 10−6 M 21 days post-immunization. Mean spot forming units ± SD are shown (n = 3 mice per group). Two-way ANOVA with Dunnett’s multiple comparison test 
was used to test for statistical significance when compared to the groups immunized with the index peptide KI.
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single immunization with the respective peptide displayed a 
similar response curve with peak responses elicited 2–3  weeks 
post-immunization (Figure  3C). It therefore appears unlikely 
that the reduced IFNγ responses following co-presentation of 
both peptides should result from different peptide kinetics. The 
implication for pathogen immune evasion is that a host exposed 
to both variants simultaneously might generate impaired IFNγ 
responses to both epitopes. This potential mutual interference 
was surprising and led us to investigate what would happen if 
mice were immunized sequentially with peptides KI and DI.
Variant Di inhibited Ki-Primed effector 
T cells In Vivo
To study in vivo effects of DI on KI-primed effector T cells, we 
primed BALB/c mice with the index peptide KI (d0) and 2 weeks 
later (d14) injected DCs presenting DI. We called this sequential 
immunization protocol KI–DI. Control mice received KI-pulsed 
DCs on day 0 (KI) or DI-pulsed DCs on day 14 (DI) or DCs without 
peptide (DC alone). KI-specific IFNγ responses were measured 
14–17 days after the last immunization by ex vivo ELISpot assay. 
Mice primed with the index variant KI that received no further 
immunizations showed strong KI-specific IFNγ responses detect-
able 31 days post-immunization (Figure 4A). Mice receiving the 
KI–DI sequential immunizations, however, had significantly 
reduced numbers of KI-specific IFNγ-secreting cells (Figure 4A, 
black bars; p < 0.01). No difference was observed in the numbers 
of KI-specific IL-4-secreting cells between mice immunized with 
KI alone or followed by DI 14 days later (Figure 4B, black bars), 
and no KI-specific IL-10 secretion was detected in any of the 
groups (Figure 4C). These results suggest that epitope variant DI 
has an inhibitory effect on polyclonal KI-primed IFNγ secreting 
but not IL-4 secreting effector T cells in vivo.
DI-specific IFNγ responses were also measured after sequen-
tial immunization. Interestingly, there were significantly fewer 
DI-specific IFNγ-secreting cells detected in mice previously 
primed with KI compared with mice that were not pre-primed 
(Figure  4A, gray bars, p <  0.001). No significant difference in 
DI-specific IL-4 secretion (Figure 4B) and no DI-specific IL-10 
secretion (Figure 4C) were observed in these mice. These results 
show that priming with the index peptide KI inhibits subsequent 
priming with the altered peptide variant DI.
No such interference was observed with AI-specific priming, 
using the above sequential immunization protocol for KI–AI 
AB
C
FigUre 3 | Pooled data. (a) BALB/c mice immunized with dendritic cells 
(DCs) pulsed with either peptide KI alone (n = 37), with DCs pulsed with KI for 
1 h followed by DI for 2 h (n = 24) or with DC pulsed with KI for 1 h then with  
AI for 2 h (n = 23). Control mice received DCs without peptide (n = 30). 
KI-specific IFNγ response was assessed by ex vivo ELISpot assay. Pooled data 
from 12 experiments are shown. Dots represent individual mice, and the 
horizontal line represents the mean ± SD. Data were analyzed using one-way 
ANOVA followed by Bonferroni’s multiple comparison test. (B) BALB/c mice 
were immunized with DCs pulsed with either peptide DI alone or with DCs 
pulsed with KI for 1 h followed by DI for 2 h. Control mice received DCs without 
peptide. DI-specific IFNγ response was assessed by ex vivo ELISpot assay. 
Pooled data from eight experiments are shown. Dots represent individual mice, 
and the horizontal line represents the mean ± SD. Data were analyzed using 
one-way ANOVA followed by Bonferroni’s multiple comparison test. (c) Mice 
were immunized with DCs pulsed with KI (black squares), DI (gray triangles), or 
AI (gray diamonds) alone and IFNγ responses to their respective peptides 
measured by ex vivo ELISpot assay at different time points. KI response is 
shown for control mice that received DCs without peptide. Mean spot forming 
units ± SD are shown (n = 3–9 mice per time point).
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immunization. KI-primed mice showed strong KI-specific IFNγ 
responses irrespective of whether they were later immunized 
with AI-pulsed DCs or not (Figure  4D, black bars) with 
no statistically significant difference in the frequencies of 
KI-specific IFNγ-secreting effector T cells between KI- and 
KI–AI-immunized mice. Variant AI had no inhibitory effect on 
KI-specific IFNγ effector responses in vivo. Similarly, KI-primed 
mice raised competent AI-specific IFNγ-secreting cells in 
response KI–AI immunization, similar to AI-immunized mice 
(Figure 4D, gray bars).
Ki-specific iFnγ responses Were 
inhibited in the Presence of epitope 
Variant Di In Vitro
The effects of antagonistic peptides have been studied on both 
clonal and polyclonal effector T cell responses (9, 14). Peptide 
variant DI has previously been shown to partially antagonize 
KI-specific IFNγ secretion in  vitro in splenocytes from mice 
immunized with KI-expressing protein particles derived from a 
yeast retrotransposon (TyS3) (9). Here, we confirm that peptide 
DI inhibits KI-specific effector T cell responses in vitro using a 
protocol optimized in previous studies to control for the issue 
of competition of peptides for binding to MHC (9, 15). For the 
antagonism assay, splenocytes from KI-immunized mice were 
incubated with the suboptimal KI concentration of 10−8  M 
(0.01  µg/mL), and after 1  h DI was added at concentrations 
ranging from 10−8 to 10−4  M. Figure  5 shows that addition of 
the altered variant DI significantly inhibited KI-specific IFNγ 
secretion from concentrations as low as 10−6 M (0.1 µg/mL). The 
inhibitory effect increased with increasing DI concentration, but 
inhibition never exceeded 60% of the total IFNγ response to the 
index peptide KI.
Ki/ai-Primed cells Were not susceptible 
to In Vivo immune interference by Di
Similar frequencies of KI-specific IFNγ-secreting cells 
were detected in the spleens from KI-immunized and KI/
AI-immunized mice, although mice primed with KI or AI 
individually showed no cross-reactivity to the other variant (data 
not shown). In order to determine whether KI-specific CD8 T 
cells, induced by co-immunization with KI/AI, would have a 
similar or distinct pattern of cross-reactivity and/or susceptibil-
ity to immune interference to those induced with KI alone, mice 
were immunized with either KI/AI together, or KI alone on DCs 
(day 0), and 2 weeks later with DI-pulsed DCs (KI/AI–DI and 
KI–DI, respectively). Control mice received DCs pulsed with KI 
or without peptide. KI-specific IFNγ responses were measured 
2–3 weeks later by ex vivo ELISpot assay. Three experiments were 
performed to assess the effect of variant DI on KI-specific IFNγ 
responses from KI/AI-primed splenocytes. The responses of mice 
immunized with KI were as expected susceptible to immune 
interference by subsequent immunization with DI (Figure 6). By 
contrast, we detected no significant difference in KI-specific IFNγ 
responses between KI/AI-primed mice that received a subsequent 
immunization with DI-pulsed DCs on day 14 and those that did 
not (Figure 6). Mice immunized with DCs presenting the variant 
AI alone on day 0 followed by immunization with DCs pulsed 
with variant DI on day 14 had no detectable KI-specific IFNγ 
responses (Figure 6), consistent with the previously shown lack 
FigUre 6 | Ki/ai-primed cells are resistant to Di-induced immune 
interference. BALB/c mice were immunized on day 0 with dendritic cells 
(DCs) pulsed with either KI or AI or with DCs pulsed with KI for 1 h followed 
by AI for another 2 h. On day 14, three groups received sequential 
immunization with DI-pulsed DCs (KI–DI, KI/AI–DI, and AI–DI). The negative 
control group received two immunizations with non-pulsed DCs 14 days 
apart. Splenocytes were assessed for KI-specific IFNγ responses by ex vivo 
ELISpot assay 17 days after boost immunization (day 31). Mean spot forming 
units ± SD are shown (n = 3 mice per group). Two-way ANOVA with 
Dunnett’s multiple comparison test was used to test for statistical significance 
when compared to the groups immunized with the index peptide KI.
FigUre 5 | Variant Di antagonizes Ki-specific iFnγ secretion in vitro. 
BALB/c mice were immunized with 106 dendritic cells (DCs) pulsed with 
peptide variant KI or with DCs without peptide as negative controls. IFNγ 
responses were measured 21 days post-immunization by ex vivo ELISpot 
assay. Splenocytes were restimulated with the index peptide KI at 10−8 M for 
1 h, followed by the altered peptide variant DI at different concentrations 
(10−8–10−4 M). Mean spot forming units ± SD are shown (n = 3 mice per 
group). Two-way ANOVA with Dunnett’s multiple comparison test was used 
to test for statistical significance when compared to the groups immunized 
with the index peptide KI.
A
B
C
D
FigUre 4 | immunization with variant Di but not variant ai inhibits 
Ki-specific iFnγ-secreting effector T cells in vivo. BALB/c mice were 
immunized with dendritic cells (DCs) pulsed with KI on day 0 (KI), DCs pulsed 
with DI on day 14 (DI) or with KI-pulsed DCs on day 0 followed by DI-pulsed 
DCs on day 14 (KI–DI). The negative control group received two 
immunizations with non-pulsed DCs 14 days apart. Splenocytes were 
assessed for KI-specific (black bars) and DI-specific (gray bars) (a) IFNγ, 
(B) IL-4, and (c) IL-10 responses by ex vivo ELISpot assay 17 days after the 
last immunization (day 31). (D) BALB/c mice were immunized with DCs 
pulsed with KI on day 0 (KI), with DCs pulsed with AI on day 14 (AI) or with 
KI-pulsed DCs on day 0 followed by AI-pulsed DCs on day 14 (KI–AI). The 
negative control group received two immunizations with non-pulsed DCs 
14 days apart. Splenocytes were assessed for KI-specific (black bars) and 
AI-specific (gray bars) IFNγ responses by ex vivo ELISpot assay 14 days after 
boost immunization (day 28). Mean spot forming units ± SD (n = 3 mice per 
group). Two-way ANOVA with Tukey’s multiple comparison test was used to 
test for statistical significance when comparing all groups (a,B,D). Two-way 
ANOVA with Dunnett’s multiple comparison test was used to test for 
statistical significance when comparing to the media control (C).
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of cross-reactivity. Our results show that KI/AI immunization, 
in contrast to immunization with KI or AI alone, induced T cells 
that recognize KI and AI, while no longer being susceptible to 
being turned off by immunization with the antagonistic DI APL, 
rendering the response therefore resistant to this type of immune 
interference.
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DiscUssiOn
The present study shows that immunization with combinations 
of highly related immunogenic variant peptides (KI, DI, and 
AI), such as those found naturally in pathogen populations with 
highly polymorphic T-cell epitopes, can have highly variable, 
and unpredictable, outcomes, with some combinations capable 
of decreasing immunity to both immunizing peptides (KI and 
DI). Moreover, immunizing sequentially with such peptides 
was shown to be capable of turning off responses, again to both 
immunizing T-cell epitope variants (KI and DI). The existence of 
“sequential immune interference” has theoretical consequences 
for pathogen population structures. It may be that polymorphic 
variants provide a survival advantage to the pathogen population 
that allows the species to evade the host immune response. By 
contrast, co-immunization of KI and AI had apparently little 
effect on the initial induction of immunity to either epitope, but, 
unexpectedly, the KI-specific responses generated were no longer 
susceptible to being turned off by subsequent immunization with 
DI. This finding offers a new practical strategy to elicit robust 
immune responses against polymorphic variants (by co-immu-
nizing with an index epitope and a carefully selected “potentiator” 
epitope), which are then further resistant to being turned off by 
natural polymorphic variants capable of immune interference. In 
vivo challenge experiments with P. berghei sporozoites are needed 
to quantify the extent to which protective immunity is altered in 
this model.
Each of the three CD8 T-cell epitopes selected for study (KI, DI, 
and AI) induced high immune responses to themselves, but not 
to the other two epitopes, thus at face value they represent simple 
non-cross-reactive T-cell epitopes. However, co-immunization 
with DC pre-pulsed with KI and DI together, significantly reduced 
responses to both epitopes, with this mutual immune interference 
observed even when KI and DI were injected separately on sepa-
rately peptide pulsed DC. There was no correlation between the 
magnitude of induced KI response and the level of interference by 
DI. Furthermore, the DI peptide was also shown to be capable of 
turning off effector KI-specific responses in a manner consistent 
with a classical APL antagonist. However, the fact that immune 
interference was observed even when presenting the epitopes on 
separate DC shows that the immune interference observed herein 
is not acting via classical mechanisms used by APL antagonism, 
such as alterations of the TCR:MHC immune-synaptosome 
structure (16). Further studies will be required to fully explore the 
extent to which immune interference by KI and DI is potentially 
fully reciprocal under a range of co-presentation and sequential 
immunization combinations.
The activity of some APL antagonist peptides has been shown 
to depend on a high off-rate in relation to MHC binding, but such 
mechanisms are unlikely to underlie the observed immune inter-
ference described in this study, since we have previously shown 
similarly high affinity binding to MHC for KI, DI, and AI (1). 
Temporal separation of stimulation by KI and DI by sequential 
immunization also resulted in reduced immunity demonstrating 
that immune interference by DI acts by stimulating KI-specific 
T cells to change their activity profile. Such switching of an activ-
ity profile has been observed in vitro for CD4 T-cell epitopes from 
P. falciparum. In this case, stimulation with a variant polymorphic 
epitope of an index peptide converted IFNγ-producing cells into 
IL-10 producers; a property demonstrated with human T cell 
clones to Th2R region variants of CS (2). In our study, immuniza-
tion with DI did not appear to switch KI-specific responses from 
IFNγ to IL-10, or convert them into IL-4-producing Th2 cells, 
which have been noted as previous APL mechanisms capable of 
down modulating Th1 and cytotoxic immunity. These results do 
not exclude the hypothesis that stimulation with DI promotes 
other, less obvious, immunosuppressive cell populations, as well 
as potentially T cell apoptosis, anergy, or partial activation, related 
in a number of other studies with low TCR affinity interactions or 
disturbed TCR stimulating signaling micro-domains [reviewed 
in Ref. (17, 18)].
By using a combination of the index variant KI together with 
the “potentiator” peptide AI, we have demonstrated the induction 
of an immune response that is resistant to immune interference 
by DI stimulation. This finding lays the experimental founda-
tions for a practical immunization strategy that could induce 
robust and long-lasting immune responses in the malaria setting. 
Thus, index epitopes could be paired with potentiator epitopes 
in a single immunization to induce a robust immune response 
to a polymorphic epitope, which would be predicted to persist 
even in vaccinees challenged by repeated pathogen stimula-
tion. This is potentially of great significance for those living in 
malaria-endemic regions and exposed to persistent reinfection 
by polymorphic parasites capable of turning off immunity using 
immune interference (1). Moreover, combinations of engineered 
and natural variants may offer a new path for vaccines against 
many different pathogens, to create new modalities of cross-
reactive responses.
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